Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. John's Wort/HIV Protease Inhibitor Use Warnings Issued By FDA, NIH

This article was originally published in The Tan Sheet

Executive Summary

HIV patients taking protease inhibitors should avoid taking St. John's wort dietary supplements, FDA and the National Institutes of Health warned Feb. 10, following the release of study results demonstrating the herbal compromises the antiviral drugs' effectiveness.
Advertisement

Related Content

St. John's wort
Valerian, Kava Anesthetic Interaction Potential Cited In JAMA Review
Herb/drug interactions
Study Protocols Should Check For Alternative Medicine Use - CDER Seminar
St. John's Wort Tolerance Superior To Rx Imipramine - German Study
Health Care Provider, Supplement Firm Interaction Urged By APhA, ADA
International St. John's wort
Supplement Labeling Safety One Of Six Guidance Topics Raised By GAO
OTC/Supplement Combinations "Serious Concern" For FDA
Botanical/Drug Interactions To Be Studied By NCCAM

Topics

Advertisement
UsernamePublicRestriction

Register

PS090868

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel